Efemoral Medical's Bioresorbable Scaffold Achieves 97% Patency Rate in Peripheral Artery Disease Trial

Key Takeaways

• Efemoral Medical’s bioresorbable scaffold demonstrated 97% primary patency at 3 years in femoropopliteal disease patients
• The device achieved a record-low 1% post-procedural residual stenosis rate, the lowest ever reported in femoropopliteal intervention trials
• Results from the 40-patient EFEMORAL I trial were presented at the Charing Cross Symposium, positioning the company for larger pivotal studies

---

Efemoral Medical announced breakthrough long-term results for its novel bioresorbable scaffold in treating femoropopliteal disease, with the device maintaining a 97% primary patency rate at three years and achieving the lowest residual stenosis rate ever recorded in clinical trials.

The Los Altos-based medical device company presented data from its EFEMORAL I trial at the Charing Cross Symposium in London on April 21, 2026. Principal Investigator Prof. Andrew Holden of Auckland, New Zealand, reported results from the first 40 patients treated with the bioresorbable scaffold technology.

Record-Breaking Clinical Performance

The most significant finding was the device’s 1% post-procedural residual stenosis rate, which Efemoral Medical claims represents the lowest rate ever reported in a clinical trial of femoropopliteal intervention. This metric, combined with the exceptional 97% primary patency at three years, suggests the technology may offer substantial advantages over existing treatment options.

Femoropopliteal disease affects the arteries running from the thigh to the knee and represents a significant portion of peripheral artery disease (PAD) cases. Current treatment options include balloon angioplasty, drug-eluting balloons, and permanent stents, but long-term patency rates have historically been challenging in this anatomical region.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for cardiovascular - peripheral artery disease. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Bioresorbable Technology Advantage

Unlike permanent metal stents, bioresorbable scaffolds provide temporary structural support during the critical healing period before being absorbed by the body. This approach potentially reduces long-term complications associated with permanent implants, including chronic inflammation and vessel rigidity.

The exceptional durability demonstrated in the EFEMORAL I trial positions the technology as a potential game-changer in peripheral interventions, where maintaining long-term vessel patency has been a persistent clinical challenge.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Implications and Next Steps

The peripheral artery disease market represents a significant commercial opportunity, with established players including Medtronic, Abbott Vascular, Boston Scientific, and BD Bard competing for market share. Efemoral Medical’s results, if validated in larger studies, could disrupt this competitive landscape.

However, the company faces typical early-stage challenges, including the need for larger pivotal trials to confirm these promising results across broader patient populations. The current 40-patient cohort, while showing exceptional outcomes, represents a relatively small sample size for regulatory approval pathways.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for cardiovascular - peripheral artery disease pricing, access, and launch sequencing.

Industry Response and Future Outlook

The presentation at the prestigious Charing Cross Symposium, a leading international meeting for vascular specialists, provides Efemoral Medical with significant visibility among key opinion leaders and potential clinical investigators for future studies.

The company’s next steps likely include designing and initiating larger randomized controlled trials to validate these preliminary results and support regulatory submissions. The exceptional performance metrics reported could justify premium pricing if confirmed in pivotal studies, potentially creating substantial value for the company and improved outcomes for patients with peripheral artery disease.

---

Frequently Asked Questions

What does this mean for patients with peripheral artery disease?

The results suggest patients may have access to a treatment option with superior long-term outcomes, including better vessel patency and lower complication rates compared to existing treatments, though larger trials are needed to confirm these benefits.

When will Efemoral Medical’s bioresorbable scaffold be available?

The device is still in clinical trials with only 40 patients treated so far. The company will need to complete larger pivotal studies and obtain regulatory approval before commercial availability, which typically takes several years.

How does this compare to existing peripheral artery disease treatments?

The 97% patency rate at 3 years and 1% residual stenosis rate significantly exceed typical performance of current treatments like drug-eluting balloons and permanent stents, though direct head-to-head comparisons in randomized trials would be needed for definitive conclusions.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease